Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Castle BiosciencesCSTL -0.06%82 Days Sales Outstanding is 39.92 as of Jun. 2026, which is 31% below its 10-year median of 58.27. GuruFocus rates CSTL with a GF Score™ of 82/100 and a GF Value™ of $29.83 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Castle Biosciences ranks better than 72.14% on this metric.
The historical rank and industry rank for Castle Biosciences's Days Sales Outstanding or its related term are showing as below:
CSTL'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.18 Med: 58.27 Max: 134.09
Current: 48.18
During the past 9 years, Castle Biosciences's highest Days Sales Outstanding was 134.09. The lowest was 48.18. And the median was 58.27.
CSTL's Days Sales Outstanding is ranked better than 72.14% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.59
vs CSTL: 48.18
Castle Biosciences's Days Sales Outstanding
declined
from Jun. 2025 (57.52) to Jun. 2026 (39.92).
Castle Biosciences (NAS:CSTL) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Castle Biosciences Days Sales Outstanding Related Terms
Castle Biosciences Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Castle Biosciences's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSTL vs OPK, FLGT, FRNM: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Castle Biosciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's Days Sales Outstanding falls into.
Castle Biosciences Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Castle Biosciences (CSTL) has a Days Sales Outstanding of 39.92 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Castle Biosciences and its competitors. This is 31% below median its historical median of 58.27. Over the past decade, Castle Biosciences' Days Sales Outstanding has ranged from 48.18 to 134.09. According to the industry distribution chart, Castle Biosciences ranks #56 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 27.9%.
Is Castle Biosciences' Days Sales Outstanding too high?
Castle Biosciences' current Days Sales Outstanding of 39.92 is 31% below median its 10-year median of 58.27. Over the past 10 years, this metric has ranged from a low of 48.18 to a high of 134.09. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.59. Castle Biosciences' value of 39.92 is 40.9% below this industry median. Based on the distribution chart, Castle Biosciences ranks #56 out of 201 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Castle Biosciences has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Days Sales Outstanding compare to OPK and FLGT?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #56 out of 201 companies for Days Sales Outstanding. This puts Castle Biosciences in the upper half of its industry. The industry median Days Sales Outstanding is 67.59. Castle Biosciences' value of 39.92 is 40.9% below this benchmark. Historically, Castle Biosciences' own Days Sales Outstanding has ranged from 48.18 to 134.09 over the past decade. While the company's 10-year median is 58.27 vs. the industry median of 67.59, Castle Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.59, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Castle Biosciences's current Days Sales Outstanding of 39.92 is 40.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Castle Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Castle Biosciences's current Days Sales Outstanding is 39.92, which is 31% below median its own 10-year median of 58.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.83, compared to a current price of $35.48 — trading 18.9% above its estimated fair value. The current Days Sales Outstanding is 39.92, which is 31% below median its 10-year median of 58.27 and 40.9% below the Medical Diagnostics & Research industry median of 67.59. Castle Biosciences' overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Days Sales Outstanding is 39.92 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (CSTL) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be overvalued.
The current stock price of $35.48 is trading 18.9% above its estimated GF Value™ of $29.83.
GuruFocus considers Castle Biosciences to be Modestly Overvalued.
Key valuation signals for CSTL:
Days Sales Outstanding: 39.92 (31% below median its 10-year median of 58.27)
GF Value™: $29.83 vs. price of $35.48 (18.9% above fair value)
Industry Position: 40.9% below the Medical Diagnostics & Research median (#56 of 201)
No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
82GF Score
Get the complete analysis for CSTL
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSTL has been successfully added to your 
